# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst David Lebovitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from...
B of A Securities maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $248 to $295.
Leerink Partners maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Market Perform and raises the price target from $138 ...
TD Cowen analyst Ritu Baral maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $260...
Evercore ISI Group analyst Liisa Bayko maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the pric...
Barclays analyst Gena Wang maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target fro...
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target ...
Wells Fargo analyst Tiago Fauth maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price tar...
Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price ...